Titan Pharmaceuticals (TTNP)
(Delayed Data from NSDQ)
$5.30 USD
-0.03 (-0.47%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.13 -0.17 (-3.21%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Titan Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 2 | 5 | 4 |
Cost Of Goods | 0 | 0 | 0 | 0 | 1 |
Gross Profit | 0 | 1 | 1 | 4 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 7 | 11 | 11 | 12 | 19 |
Income After Depreciation & Amortization | -7 | -10 | -9 | -7 | -17 |
Non-Operating Income | 2 | 0 | 1 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 1 | 1 |
Pretax Income | -6 | -10 | -9 | -7 | -16 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -6 | -10 | -9 | -7 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | -11 | 0 |
Net Income (GAAP) | -6 | -10 | -9 | -18 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -10 | -9 | -7 | -17 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -7 | -10 | -9 | -7 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.75 | 0.67 | 0.49 | NA | 0.04 |
Diluted EPS Before Non-Recurring Items | -7.41 | -15.20 | -19.40 | NA | -432.43 |
Diluted Net EPS (GAAP) | -7.41 | -15.20 | -18.00 | -96.60 | -432.43 |
Fiscal Year end for Titan Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
SG&A, R&D, and Dept/Amort Expenses | 2.07 | 1.06 | 1.93 | 2.06 | 1.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.07 | -1.06 | -1.93 | -2.06 | -1.59 |
Non-Operating Income | -0.02 | 0.00 | -0.04 | 1.72 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.09 | -1.06 | -1.97 | -0.34 | -1.59 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.09 | -1.06 | -1.97 | -0.34 | -1.59 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.09 | -1.06 | -1.97 | -0.34 | -1.59 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 0.91 | 0.85 | NA | 0.75 | 0.75 |
Diluted EPS Before Non-Recurring Items | -2.29 | -1.24 | NA | -0.40 | -2.20 |
Diluted Net EPS (GAAP) | -2.29 | -1.24 | -2.61 | -0.40 | -2.20 |